菜单

Locations & Facilities

As a leading global CRDMO, with over 12,000 skilled employees in the United States, Ireland, Germany, China and Singapore, WuXi Biologics provides an extensive R&D and manufacturing network to support our clients worldwide.
  • 5 Research Centers
  • 8 Development Centers
  • 8 Manufacturing Centers

Boston

  • Capability

    • Boston Research Service Center offers early-stage biologics discovery services with capabilities in antibody development, high-throughput screening, and in vitro pharmacology.
  • Strategic Location

    • Located in the heart of USA biotechnology to support Boston-area innovators with faster turnaround and flexible discovery-stage solutions.
  • Operational Scale

    • Operational since 2023

ABI-LAB in Natick, MA, USA

Cranbury

Cranbury, New Jersey, USA

  • Strategic Location

    • Located in the New Jersey-New York-Pennsylvania biopharmaceutical corridor
    • Proximity to USA client headquarters
  • Operational Scale

    • Total area of 14,340 m²
  • Track Record

    • 100% success rate in delivering 30+ DS/DP batches
    • Passed 40+ Client GMP audits
One-stop end to end capability from DNA to BLA

Early and late stage process development
Formulation and drug product development
Comprehensive Analytical and QC Panel
clinical and commercial DS manufacturing
clinical and commercial DP manufacturing
DS Manufacturing

Fed batch, Intensified fed batch, and WuXiUP™ processing
200-2x2000L Single Use Bioreactors
36 batches annual capacity

DP Manufacturing

Vanrx Robotic Filling Isolator
Liquid filling in 2R, 6R, 10R Vials, 1ml, 2.25 ml PFS
Up to 20,000 dose max batch size
50 batches annual capacity

Chengdu

Wenjiang District, Chengdu, China

  • Strategic Location

    • Located in Wenjiang life sciences and wellness cluster
    • WuXi Biologics’ largest site in Southwest China
  • Operational Scale

    • Protein science labs operational since 2022
    • Microbial commercial manufacturing site started construction in 2025 and expected to complete GMP release in 2H 2026
    • Covering a total built-up area of approximately 95,000 m²

Capacity

 
15,000 L bioreactor capacity
for GMP drug substance production

dual-chamber lyophilized
preparation and vial production

Capability

15,000 L fermenter that expands to 60,000 L

China’s first dual-chamber lyophilization line and a vial filling line, annual drug product capacity
over 10 million vials

EffiXTM microbial expression system for high-yield, high-quality, and scalable biologics development and production

Dundalk

Dundalk, Ireland

  • Strategic Location

    • Ireland is a leading global biopharma hub with top talent, strong compliance, and the world’s top pharma companies
    • Dundalk site strategically positioned on the Dublin–Belfast M1 corridor with direct international connectivity
    • M1 Corridor offers exceptional talent access, multimodal transport, and a mature biopharma ecosystem within a 60-minute radius
  • Operational Scale

    • WuXi Biologics' Ireland Site is Ireland’s first site capable of large-scale commercial biologics drug substance production for global partners
    • A 26‑hectare campus featuring a 47,000‑square‑meter facility
    • 800 jobs created

Capacity

 
MFG6.1 and MFG6.2: Combined 6,000 L
perfusion capacity

MFG7: WuXi Biologics’ largest single-use, fed‍-‍batch facility in Europe, with 48,000 L fed-batch capacity

Capability

 
Received EMA and HPRA
GMP authorization

Successful completion of multiple 16,000 L Process Performance Qualification and commercial batches

QC lab: Standalone releasing testing capability

Hangzhou (MVP)

Hangzhou, China

  • Strategic Locations

    • Located within the Yangtze River Delta and boasts integrated connectivity with access to major markets
  • Operational Scale

    • MFG13 and MFG14 for clinical and commercial drug substance manufacturing
    • DP8 for drug product fill-finish
    • Operational since 2020

Capacity

 
MFG13: 2,600 L HEK293 FB/Perfusion/CFB;
360 L Microbial FB

MFG14: 4,460 L
microbial FB

DP8: Liquid vial/PFS (Vanrx, 1M dose) (2M dose)
/20 L GMP LNP Capability

Capability

EffiXTM microbial expression system for high-yield, high-quality, and scalable biologics development and production
WuXia293Stable TM Platform for the efficient expression and development of complex biopharmaceutical molecules.
Advanced LNP technical platform providing end-to-end services from plasmid construction, LNP formulation optimization to encapsulation and DP manufacturing
Provide one-stop, end-to-end services from strain development to regulatory filing and beyond

Hangzhou (MFG)

Economic Development Zone, Hangzhou, China

  • Strategic Locations

    • Located within the Yangtze River Delta and boasts integrated connectivity with access to major markets
  • Operational Scale

    • MFG20 for clinical and commercial drug substance manufacturing
    • DP9 for clinical and commercial drug product fill-finish
    • Operational since 2021

Capacity

MFG20 total capacity: 23,000 L
Asia‘s first 3 × 5,000 L line,
with state‍-‍of‍-‍the‍-‍art DynaDrive Single‍-‍Use Bioreactor, and multiple impellers coupled with DHS, allowing wide scalability and improved controls

4 x 2,000 L single‍-‍use bioreactors enabling flexible production scheduling via concurrent production

DP9: Liquid and lyophilized vials (6 M dose, lyo 1 x 10 m²)

Capability

 
100%
manufacturing successful rate

In 5,000 L line, with state-of-the-art DynaDrive Single-Use Bioreactor, and multiple impellers coupled with DHS, allowing wide scalability and improved controls
4 x 2,000 L single-use bioreactors enabling flexible production scheduling via concurrent production

Hebei

Hebei, China

  • Strategic Location

    • Located in a Hi-Tech Industrial Development Zone
    • WuXi Biologics’ largest site in Northern China, strengthening global footprint and extending reach to Northern markets
  • Operational Scale

    • GMP operation since 2022

Capacity

 
12 x 4,000 L
single-use bioreactors

Fed-batch production from 4,000 to 20,000 L

Capability

 
100%
success rate

Factory of the future: A digital system optimizes carbon reduction, reuse, and recycling while rooftop solar systems cuts annual carbon emissions by hundreds of tons.

Shanghai Waigaoqiao FTZ

Waigaoqiao Free Trade Zone, Shanghai, China

  • Strategic Location

    • Customs facilitation
    • Industrial co-location benefits
    • Policy incentives
  • Operational Scale

    • Operational since 2010
    • MFG3 Drug substance manufacturing

Capacity

 
MFG3: 9,000L Clinical Drug Substance Manufacturing (50L – 2*2,000L)
  • Intensified Perfusion
  • Fed-Batch
  • Perfusion
  • Intensified Fed-Batch

Capability

Comprehensive biologics discovery, development,
and manufacturing in 1 convenient location
EMA-certified cell banking suites

Full spectrum of biologics research and process development services

Exclusive technology platforms:
WuXia™, WuXia™ TrueSite and another two extended platforms for cell line development
WuXiUP™ for continuous bioprocessing
WuXiHigh™ for high concentration & HT DP

Digitalization & Automation
  • Electronic Batch Record
  • Process Analytical Technology

MFG3 passes 6 times NMPA audits, 100% success rate

Shanghai Fengxian

Fengxian District, Shanghai, China

  • Strategic Locations

    • Located in Biotech Cluster
  • Operational Scale

    • CRDMO center
    • 1,000+ skilled employees
    • Labs operational since 2021; DAC operational since 2023
    • MFG17 Drug substance manufacturing
    • DP14 & DP15 Drug product manufacturing

Capacity

 
9,500 L

MFG17: 9,500L Clinical Drug Substance Manufacturing (50L – 2*2,000L)
DAC (Device Assembly Center) with assembly and labeling capabilities for combo products
DP14 and DP15 for drug product fill-finish

Capability

Full spectrum of biologics research and process development services

Exclusive technology platforms:
WuXiBody™ for bispecific antibody discovery
SDArBody™ for multispecific antibody discovery
WuXia™, WuXia™ TrueSite and another two extended platforms for cell line development
WuXiUP™ for continuous bioprocessing

Autoinjector assembly, NSD assembly and manual syringe assembly

PFS and vial production line

Digitalization & Automation
  • ElectronDigitalization & Automation ic Batch Record
  • Process Analytical Technology

Shanghai Lingang Biosafety Testing Center

  • Capability

    • Viral clearance studies (includes animal sourced medical device)
    • Cell bank characterization
    • Unprocessed bulk testing
    • Additional biosafety testing
    • Equip with Cryo-TEM compliant to BSL-2 and cGMP standard
  • Strategic Location

    • Direct proximity to container terminal and Shanghai Pudong International Airport for rapid logistics
    • Synergistic collaboration with Shanghai Waigaoqiao and Fengxian sites for enhanced industrial efficiency
    • Located within Shanghai Lingang FTZ with policy incentives and industrial co-location benefits
  • Operational Scale

    • Operational since 2022
    • Over 8,000 sq. m.

Lingang Free Trade Zone, Shanghai, China

Singapore

Tuas Biomedical Park, Singapore

  • Strategic Location

    • Singapore ranks among the top-tier pharmaceutical production hubs and serves as a strategically critical node for global innovative drug manufacturing and supply chain resilience
  • Operational Scale

    • 13.5-hectare CRDMO center
    • Expected to employ 1,500 people when fully operational

Capacity

DP Manufacturing

Designed to process a wide range of finished dosage forms, including:
  • Lyophilized Vial Line (Isolator) with 2 × 20 m² lyophilizers, delivering 4–14 million lyophilized vials annually
  • Liquid Vial Line (Isolator) designed to handle up to 21 million liquid vials per year
  • Three Pre-Filled Syringes Lines (isolators with automated bag and tub openers), each capable of producing 24 million units annually
Optimized for automated, semi-automated, and manual inspection, ensuring flexibility and efficiency for diverse product types and client needs

DS Manufacturing

  • Designed with up to 120,000L cell culture capacity using 5000/6000L single use Production Bioreactors, supporting 120kg harvest protein per batch with a 2 day TAT
  • Supports TFB, IFB, and provisioned for intensified process platform
  • Enables concurrent Upstream operations, pre viral/post viral Downstream segregation, stainless steel DSP systems and Hybrid media/buffer preparation systems

Capability

One of WuXi Biologics’ 3 major CRDMO hubs

Meets Singapore’s GREEN Mark GoldPLUS rating

Finished building will be one of the world’s largest modular biologics DP facilities

Suzhou Biosafety Testing Center

  • Capability

    • Biosafety Testing Center (among the first in Asia)
    • China’s only EMA- and FDA-audited biosafety testing center
    • Viral clearance studies
    • Cell bank characterization
    • Unprocessed bulk testing
    • Additional biosafety testing
  • Strategic Location

    • Proximity to Shanghai, integrated transportation networks
    • Robust biopharmaceutical ecosystem
  • Operational Scale

    • Operational since 2014
    • Over 16,000 sq. m.

Wuzhong District, Suzhou, China

Suzhou Industrial Park

Industrial Park, Suzhou, China

  • Strategic Location

    • Proximity to Shanghai, integrated transportation networks
    • Robust biopharmaceutical ecosystem
  • Operational Scale

    • MFG21 for drug substance manufacturing
    • DP11 for drug product fill-finish
    • Operational since 2021
    • Co-location: Drug Substance & Drug Product manufacturing in ONE building

Capacity

 
  • MFG21: 7,300L Clinical Drug Substance
    Manufacturing (50L – 2*2,000L)
  • DP11: Liquid and lyophilization vials (10M dose, Lyo 1x 12m2)

Capability

 
Four upstream production lines and 2 downstream
purification lines, meeting production for
various project scales and types

Fully automated filling for
drug product fill and lyophilization

Worchester

Worchester, MA, USA

  • Strategic Location:

    • Integration with our Cranbury, NJ site and Boston Research Center for end-to-end USA service
  • Operational Scale

    • 17,605 m² drug substance manufacturing

Capacity

 
 
Six 6,000 L
upstream tanks connected to 1 downstream line

Capability

 
One of the largest single-use-technology facilities in the USA

High-throughput processing and
extensive automation

Clinical- and commercial-scale manufacturing compliant with cGMP

Wuppertal

Wuppertal, Germany

  • Strategic Location

    • Located in the Ruhr Industrial Region, one of Europe’s largest industrial hubs
    • Adjacent to the Cologne-Düsseldorf metropolitan area
    • One-hour access to multiple international transport gateways
  • Operational Scale

    • 30,000 m² drug substance production
    • Staffed by highly skilled experts

Capacity

 
 
MFG19: 24,000 L capacity (6 x 2,000 L current, 6 more planned) with single-use bioreactors supporting FB/CFB and perfusion culture

Capability

State-of-the-art cGMP drug substance plant with modular production platform for monoclonal antibodies

QC labs: DS in-process testing, DS release and stability testing

On-site MSAT enabling seamless tech transfer from PD, global manufacturing sites, or client-originated processes to MFG19

Robust material supply: on-site warehouse and outsourced warehouse within a 30-minute drive

WuXi XDC (Wuxi)

  • Capacity

      Conjugation Drug Substance Production (“XBCM”) and Antibody Intermediates Production (“XmAb”)

    • XBCM1 facility with single-use reactor systems ranging from 5 L to 500 L and the redesigned reactor system with additional DS capacity, commenced operation in 1H 2025.
    • The dual function XmAb/XBCM2 (“XBCM2 Line 1”) facility is designed with capacities ranging from 50 L to 2,000 L per batch for monoclonal antibody intermediates or 2,000 L of drug substance per batch. A second line (“XBCM2 Line 2”), also with dual function design, commenced operation in November 2024.

      Conjugation Drug Product Production (“XDP”)

    • XDP1 facility is designed to produce three million doses of bioconjugates per year in liquid or lyophilized form (3 million vials, lyophilizer 1x5 m² & 1x20 m² ).
    • XDP2 facility is designed to produce five million doses of bioconjugate drug products per year in liquid or lyophilized form (5 million vials, lyophilizer 1x5 m² & 2x20 m² ).
    • XDP3 facility i s designed t o produce seven million doses of bioconjugate drug products per year in liquid or lyophilized form (7 million vials, lyophilizer 2x30 m² ).
    • XDP5 facility i s designed to produce twelve million doses of bioconjugate drug products per year in liquid or lyophilized form (12 million vials, lyophilizer 4x30 m² ) and is expected to commence operation in 2027.

      Payload Linker (“XPLM”)

    • XPLM1 facility is designed as a kilogram-scale payload and linker production line.
  • Capability

    • GMP-compliant production
    • Formulation and analytical development
    • QC release and stability testing

Wuxi, China

WuXi XDC (Singapore)

  • Capacity

    • Conjugation Drug Substance Production: Dual function XmAb/XBCM3 facility (50 L to 2,000 L per batch for monoclonal antibody intermediates; up to 2,000 L per batch for bioconjugate drug substance, expected to commence GMP manufacturing in 2026)
    • Conjugation Drug Substance Production: XBCM4 production line (up to 500 L of bioconjugate drug substance per batch, expected to commence GMP manufacturing in 2026)
    • Conjugation Drug Product Production: XDP4 facility (8 million doses of bioconjugates per year in liquid or lyophilized form; 200-300 vials per minute for liquid or lyophilized drug products (8 million vials, lyophilizer 1×10 m² & 2×30 m²), expected to commence operation in 2026)
  • Capability

    • Clinical or commercial manufacturing of antibody intermediates, drug substance and drug product

Tuas Biomedical Park, Singapore

WuXi XDC (Shanghai)

  • Capacity

    • Bioconjugate discovery, research and process development (with dedicated laboratories for bioconjugate discovery and process development)
    • Analytical and formulation development
    • Scale-up conjugation
  • Capability

    • Discovery Lab: Bioconjugate discovery and support functions
    • Bioconjugate Process Development Lab: Bioconjugate process development, analytical method development; laboratory-scale sample preparation to pilot-scale manufacturing of ADCs and other bioconjugates

Waigaoqiao Free Trade Zone, Shanghai, China

WuXi XDC (Changzhou)

  • Capacity

    • Payload-linker laboratory with a field-tested containment design to safely handle highly potent compounds that are designated as OEB (occupational exposure band) 5-rated materials
    • Reaction kettles for GMP-compliant production (up to 150 liters per batch, enabling kilogram scale payloads and linkers production)
  • Capability

    • Payload-linker discovery, research, process and analytical development
    • Payload-linker pilot-scale synthesis
    • Payload-linker GMP-compliant production

Changzhou, China

Wuxi Mashan

Mashan Biology Medical Industry Park, Wuxi, China

  • Strategic Location

    • Located in Mashan Biology Medical Industry Park
    • Proximity to Shanghai facilities, seamless multimodal logistics
  • Operational Scale

    • Drug substance and drug product manufacturing
    • Operational since 2012

Capacity

DS
MFG1 (15,500 L)
MFG2 (32,000 L)
MFG4 (11,000 L)
MFG5 (64,000 L)

DP
DP1 (Liquid and lyophilized vials 6M dose, lyo 1 x 5 m2)
DP2 (Liquid and lyophilized vials 10M dose, lyo 2 x 20 m2)
DP4 (Liquid vial/PFS Vanrx, 1M dose)
DP5 (PFS 17M~20M)
DPPC: Semi‍-‍Automatic Vial Packaging line 1 (3M Dose); Automatic Vial Packaging line 2(20M Dose); Semi‍-‍Automatic Vial Packaging line 3 (7M Dose); Manual syringe assembly (1M Dose); Semi PFS & NSD assembly (10M Dose)

Capability

 
 
Early- and late-stage process development

Clinical- and commercial-scale
GMP manufacturing

FDA and EMA approval for commercial manufacturing—the first Chinese biologics facility to receive both

The largest biopharmaceutical drug substance (DS) and drug product (DP) manufacturing site in China

WuXiUITM platform for Ultra-Intensified FB bioprocessing

WuXi Vaccines

  • Capacity

      Drug Substance

    • MFG23 BSL-1: Cell culture platform (50 L, 250 L, 500 L, 1,000 L Single Use Bioreactor); Microbial platform (200 L Stainless Steel Fermenter, expandable to 500 L)
    • MFG23 BSL-2: Microbial platform (100 L stainless steel fermenter, expandable to 200 L); Viral platform (T-flasks, cell factory, and up to 500L Single Use Bioreactor)

      Drug Product

    • DP16: Liquid and lyophilized products; equipped with 1 × 5 m² lyophilizer; capable of suspension and emulsion filling (filling volume: 1 - 20 L for small volume DS suspension, up to 200 L for liquid, up to 50 L for suspension and emulsion)
    • DP17: Liquid and lyophilized products; equipped with 3 × 25 m² lyophilizers; capable of suspension and emulsion filling; annual capacity up to 30 million vials
  • Capability

    • Process development and tech transfer services for prophylactic products
    • Clinical and commercial manufacturing services for drug substance and drug product, covering cell culture (suspension and adherent), microbial, live attenuated virus, and viral vector platforms
    • High-speed fill-and-finish & lyophilization capabilities for liquids, suspensions, and emulsions
    • Quality Control & Analytical Development lab capable of multi-platform method development, product testing, release, and stability studies
    • Quality systems in compliance with FDA, EMA, WHO, NMPA, ANVISA standards
    • Support various product types: prophylactic antibodies, subunit vaccines, nanoparticle vaccines, live attenuated vaccines, viral vector vaccines, Outer Membrane Vesicles (OMV) vaccines, conjugate vaccines, biological products that require development and production under BSL2 environment, and more
  • Strategic Location

    • 1.5-hour drive from Shanghai Pudong International Airport
    • Located in Suzhou Industrial Park

Industrial Park, Suzhou, China

Connect with our Experts

Let’s discuss your project needs.